OLFOCopy

• DRUGBANK - Budesonide
• indication:

  For the treatment of mild to moderate active Crohn's disease. Also for the treatment of asthma, non-infectious rhinitis (including hay fever and other allergies), and for treatment and prevention of nasal polyposis.

• pharmacology:

• mechanism:

  The exact mechanism of action of budesonide in the treatment of Crohn's disease is not fully understood. However, being a glucocorticosteroid, budesonide has a high local anti-inflammatory effect.

• toxicity:

  Single oral doses of 200 and 400 mg/kg were lethal in female and male mice, respectively. The signs of acute toxicity were decreased motor activity, piloerection and generalized edema.

• absorprion:

  Absorption is complete following oral administration.

• halflife:

  2.0 and 3.6 hours

• roouteelimination:

  Budesonide is excreted in urine and feces in the form of metabolites.

• volumedistribution:

  * 3 L/kg [asthmatic children 4 to 6 years of age]

• clearance:

  * 0.5 L/min [Athmatic children 4 to 6 years of age]